Salute e Benessere
ROZLYTREK's Market Growth Reflects Transforming Treatment for NTRK and ROS1-Positive Cancers | DelveInsight
ROZLYTREK is a tumor-agnostic therapy that introduces a novel approach to cancer treatment. Its active ingredient, entrectinib, inhibits tropomyosin receptor tyrosine kinases (TRKA, TRKB, and TRKC), which are encoded by the NTRK1, NTRK2, and NTRK3 genes. It also targets ROS1 and ALK, with IC50 values ranging from 0.1 to 2 nM, while showing weaker inhibition of JAK2 and TNK2 (IC50 > 5 nM). The primary active metabolite, M5, exhibits similar inhibitory activity against TRK, ROS1, and ALK.
Fusion proteins involving TRK, ROS1, or ALK kinase domains can promote tumor growth by excessively activating downstream signaling pathways, leading to uncontrolled cell proliferation. Entrectinib has demonstrated both in vitro and in vivo efficacy in inhibiting cancer cell lines across multiple tumor types carrying NTRK, ROS1, or ALK fusions. Additionally, it achieves steady-state brain-to-plasma concentration ratios between 0.4 and 2.2 in animal studies (mice, rats, and dogs) and has shown anti-tumor effects in mice with intracranial tumors driven by TRKA and ALK.
ROZLYTREK is an orally administered, once-daily treatment approved for NTRK fusion-positive solid tumors and ROS1-positive NSCLC in several countries, including Australia , Canada , the EU, Israel , Japan , New Zealand , South Korea , Taiwan , and the US, with additional regulatory reviews ongoing worldwide.
The recommended ROZLYTREK dosage for ROS1-positive NSCLC is 600 mg once daily, with or without food, until disease progression or unacceptable toxicity. For NTRK fusion-positive solid tumors, the ROZLYTREK dosage guidelines are as follows:
JP: 2019
Learn more about ROZLYTREK projected market size for ROS1 NSCLC @
Receptor Tyrosine Kinase (ROS1) is an essential transmembrane receptor protein that regulates key cellular functions such as apoptosis, survival, differentiation, proliferation, migration, and transformation. It plays a pivotal role in various cancers, including glioblastoma, colorectal cancer, gastric adenocarcinoma, inflammatory myofibroblastic tumor, ovarian cancer, angiosarcoma, and NSCLC.
A ROS1 inhibitor is a drug designed to block the activity of abnormal ROS1 fusion proteins present in certain cancer cells. By inhibiting this protein, these inhibitors help restrict cancer cell growth and metastasis. As a type of targeted therapy, ROS1 inhibitors also act on multiple kinases, including Anaplastic Lymphoma Kinase (ALK) and Mesenchymal Epithelial Transition (MET), alongside ROS1. These inhibitors specifically target the kinase domain of ROS1, with conventional kinases classified into DFG-in (active, type I) and DFG-out (inactive, type II) based on their domain structure. For patients with stage IV ROS1-positive NSCLC, treatment with a ROS1 tyrosine kinase inhibitor (TKI) is recommended.
ROS1 inhibitors have demonstrated remarkable efficacy in treating NSCLC, encompassing both approved therapies and emerging treatments under development. They have significantly advanced NSCLC management, establishing themselves as a crucial therapeutic approach. The current market for ROS1-positive NSCLC is largely dominated by TKIs such as .
According to DelveInsight's analysis, the market size for ROS1 inhibitors in NSCLC across the 7MM was valued at approximately in 2023, with the United States contributing the largest share. The market for ROS1 inhibitors is projected to experience substantial growth in the coming years. This expansion is driven by rising biomarker testing rates, a growing number of cancer diagnoses, increased awareness of ROS1 mutations, and the introduction of next-generation ROS1 TKIs. These advanced therapies offer improved CNS penetration and a broader range of coverage against ROS1 resistance mutations compared to first-generation TKIs.
Discover more about the ROS1 inhibitors market in detail @
The promising ROS1 inhibitors in the pipeline that will give tough competition to Roche's ROZLYTREK include (Nuvation Bio/Innovent Biologics/Daiichi Sankyo/Nippon Kayaku), (Nuvalent), (Avistone Biotechnology), (Jazz Pharmaceuticals), (Promontory Therapeutics), and others.
In announced that the US FDA had granted the application Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 2025 . The company is preparing for a launch as early as mid-2025.
To know more about the number of competing drugs in development, visit @
Discover how ROZLYTREK is shaping the ROS1 NSCLC treatment landscape @
ROZLYTREK competitive positioning in the market is driven by its , allowing it to cater to multiple rare cancers with a single therapy. The drug has gained regulatory approval in major markets, including the US, Europe , and Japan , benefiting from an . Its key competitor, , has a similar mechanism of action but differs in pharmacokinetics and tolerability, creating a nuanced competitive landscape.
Market adoption of ROZLYTREK is influenced by the , which facilitates the identification of eligible patients with NTRK or ROS1 fusions. However, its commercial success is partially constrained by the rarity of these genetic alterations, which limits the addressable patient population. Additionally, the in certain healthcare systems can impact uptake. Nonetheless, increasing awareness and advancements in diagnostic infrastructure are expected to support market growth.
From a strategic perspective, Roche has leveraged partnerships and real-world evidence to expand the drug's adoption. The company is actively working on to maximize ROZLYTREK's commercial potential. Additionally, the in routine cancer diagnostics may boost the identification rate of eligible patients, driving future market penetration.
The competitive landscape could see further evolution with the , particularly next-generation agents designed to address resistance mutations. However, position it well in the precision medicine segment. As personalized oncology continues to gain traction, the will depend on physician awareness, diagnostic advancements, and favorable pricing and reimbursement strategies.
Dive deeper to get more insight into ROZLYTREK's strengths & weaknesses relative to competitors @
report deliver an in-depth understanding of the market trends, market drivers, market barriers, and key ROS1 inhibitors companies, including among others.
report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NSCLC companies including among others.
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key non-small cell lung cancer companies, including among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
Shruti Thakur
info@delveinsight.com
+14699457679
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/rozlytreks-market-growth-reflects-transforming-treatment-for-ntrk-and-ros1-positive-cancers--delveinsight-302399330.html